Skip to main content

Table 1 Baseline characteristics

From: Analysis of the kinetics of the parathyroid hormone, and of associated patient outcomes, in a cohort of haemodialysis patients

 

No PTH decrease N = 67

Spontaneous PTH decrease N = 70

Medical PTH decrease N = 50

Surgical PTX N = 10

Age (years)

66.8 ± 14

71.2 ± 12

64.1 ± 16

51 ± 15 *

Female gender (%)

46.3

27.1 *

53.1

40

Dialysis vintage (months)

75.1 ± 98

71.5 ± 73

53 ± 61 *

90.5 ± 94

Diabetes (%)

37.3

41.4

24.5 *

0 *

Cardiac disease (%)

28.4

30

10 *

10 *

Peripheral vascular disease (%)

27

25

8 *

0 *

Stroke (%)

9

13

4 *

0 *

Cancer (%)

7

16

16.3

10

BMI (kg/m2)

25.8 ± 5

24.7 ± 5

24.6 ± 4

25 ± 4

Body weight (kg)

71.1 ± 18

69.7 ± 16

67.4 ± 13

70.5 ± 17

Dialysis session time (min)

330 ± 95

322 ± 90

327 ± 92

410 ± 100 *

Central catheter (%)

13.4

20

12.5

10

HDF (%)

40.3

40.3

39.6

12.5 *

Dialysate calcium (mmol/L)

1.5 ± 0.16

1.47 ± 0.16

1.53 ± 0.14

1.7 ± 0.18 *

spKt/V

2.3 ± 0.7

2.1 ± 0.6

2.4 ± 0.7

2.7 ± 1 *

nPNA (g/kg/day)

1.42 ± 0.6

1.14 ± 0.2

1.3 ± 0.4

1.43 ± 0.3

PTH (pg/mL)

198.6 ± 152

218 ± 126

280 ± 144

498 ± 315 *

Calcaemia (mmol/L)

2.26 ± 0.14

2.23 ± 0.14

2.25 ± 0.12

2.31 ± 0.12

Phosphataemia (mmol/L)

1.42 ± 0.3

1.34 ± 0.36

1.36 ± 0.3

1.26 ± 0.2

b-ALP (μg/L)

18 ± 10

21 ± 15

19 ± 11

35.6 ± 27 *

25-OHD (nmol/L)

106 ± 49

112 ± 39

104 ± 41

120 ± 28

Serum Albumin (g/L)

33.5 ± 4

31.1 ± 4

33.8 ± 4

36.8 ± 3 *

C-reactive protein (mg/L)

11.7 ± 16

14.6 ± 18

7.6 ± 8

4.3 ± 3 *

Cholecalciferol (%)

90.5

92.3

93.3

90

Alfacalcidol % (μg/week)

10 (2.2)

10 (1.6)

25 (2.5)

50 (2.9) *

CacCO3 % (g/day)

27 (1.2)

16 (1.1)

30 (2)

30 (2.4)

Sevelamer % (g/day)

39 (1.8)

21 (1.2)

37 (1.8)

20 (2)

Cinacalcet % (mg/day)

22 (35)

7 (30)

6 (39)

50 (60) *

  1. *P < 0.05; **P < 0.005 with at least one other value